Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls
Section snippets
Contributors
Xu-Feng Huang, Xiang Yang Zhang, Yun-Long Tan and Hui-Mei An were responsible for the study design, statistical analysis and manuscript preparation. Hongzhen Fan, FengMei Fan, Shu-ping Tan, Jing Shi, Zhi-Ren Wang and Fu-De Yang were responsible for recruiting the patients, performing the clinical rating and collecting the samples. LuPing Zhou, Yinghua Yu and Boz Zehre were involved in evolving the ideas and editing the manuscript. Xu-Feng Huang, Xiang Yang Zhang, Yun-Long Tan and Hui-Mei An
Role of funding source
This study was supported by grants from the National Natural Science Foundation of China (81461130016 and 81371477), the Natural Science Foundation of Beijing Municipality (7151005 and 7132063), Beijing Municipal Excellent Talents Foundation (2014000021469G218), these sources had no further role in the study design, data collection and analysis, decision to publish, or preparation of the article.
Conflict of interest statement
The authors have no conflicts to disclose.
Acknowledgment
The authors would like to thank Ning Fan for her hard work and significant contributions towards the study.
References (10)
- et al.
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia
Am. J. Hum. Genet.
(2003) - et al.
Disturbances in cell recognition molecules (N-CAM and L1 antigen) in the CSF of patients with schizophrenia
Exp. Neurol.
(1995) - et al.
The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system
Exp. Gerontol.
(1998) - et al.
NCAM1 and neurocognition in schizophrenia
Biol. Psychiatry
(2007) - et al.
Promoter variant rs2301228 on the neural cell adhesion molecule 1 gene confers risk of schizophrenia in Han Chinese
Schizophr. Res.
(2014)
Cited by (16)
Schizophrenia as autoimmune disease: Involvement of Anti-NCAM antibodies
2023, Journal of Psychiatric ResearchAutoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice
2022, Cell Reports MedicineCitation Excerpt :The extracellular region of NCAM1 is cleaved by ADAM10 and ADAM17,27,28 and a small amount of its soluble form has been found in serum. Because changes in soluble NCAM1 have been reported in patients with schizophrenia,16,17,19 we tested whether autoantibodies against NCAM1 affect the soluble form of NCAM1 in serum. We performed ELISAs to analyze soluble NCAM1 in serum and found that soluble NCAM1 is significantly reduced in patients with schizophrenia (Figure 1D).
Decreased serum NCAM is positively correlated with hippocampal volumes and negatively correlated with positive symptoms in first-episode schizophrenia patients
2020, Journal of Psychiatric ResearchCitation Excerpt :Moreover, abnormal concentrations of CSF NCAM are associated with enlarged ventricular (Vawter et al., 2001) and clinical symptoms (Lyons et al., 1988; Vawter et al., 2000). Recent studies have reported the decreased NCAM levels in CSF (Hidese et al., 2017) and serum (An et al., 2018; Zhang et al., 2014) of schizophrenia patients compared with healthy controls. One study has reported that decreased concentrations of CSF NCAM are associated with negative symptom scores in schizophrenia patients (Hidese et al., 2017).
Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia
2019, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Cognitive impairment is experienced by 75–85% of patients with schizophrenia (Barch and Ceaser, 2012) and has been recognised as a core symptom domain from which the other symptoms may arise (Kahn and Keefe, 2013). It often precedes the onset of psychotic symptoms, is evident in first episode psychosis (An et al., 2018) and can be a predictor of functional outcomes (Lepage et al., 2014). Current antipsychotic drugs (APDs) are limited in their ability to treat cognitive symptoms in schizophrenia and recent data suggests that high lifetime APD dosing potentiates cognitive deficits (Husa et al., 2017).
Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease
2018, Brain ResearchCitation Excerpt :In our previous studies, our team found that neural cell adhesion molecule (NCAM) could serve as a potential interaction partner of APP, and the interaction of APP and NCAM could modulate Aβ production (Chen and Dou, 2012; Chen et al., 2016). NCAM levels were also found to be elevated in the serum and CSF of schizophrenia patients (An et al., 2018; Lyons et al., 1988; Poltorak et al., 1995), although its role in different pathological processes was unknown. In the present study, we measured the circulating APP, NCAM, Aβ40 and Aβ42 levels to identify which biomarker or combination may be a useful, cost-effective and noninvasive biomarker for AD.
- 1
Professor Yunlong Tan and Professor Xu-Feng Huang contributed equally to this work.